Experimental treatment of antipsychotic-induced movement disorders
- PMID: 27540314
- PMCID: PMC4982503
- DOI: 10.2147/JEP.S63553
Experimental treatment of antipsychotic-induced movement disorders
Abstract
Antipsychotic drugs are extensively prescribed for the treatment of schizophrenia and other related psychiatric disorders. These drugs produced their action by blocking dopamine (DA) receptors, and these receptors are widely present throughout the brain. Therefore, extended antipsychotic use also leads to severe extrapyramidal side effects. The short-term effects include parkinsonism and the later appearing tardive dyskinesia. Currently available treatments for these disorders are mostly symptomatic and insufficient, and are often linked with a number of detrimental side effects. Antipsychotic-drug-induced tardive dyskinesia prompted researchers to explore novel drugs with fewer undesirable extrapyramidal side effects. Preclinical studies suggest a role of 5-hydroxytryptamine (serotonin)-1A and 2A/2C receptors in the modulation of dopaminergic neurotransmission and motivating a search for better therapeutic strategies for schizophrenia and related disorders. In addition, adjunctive treatment with antioxidants such as vitamin E, red rice bran oil, and curcumin in the early phases of illness may prevent additional oxidative injury, and thus improve and prevent further possible worsening of related neurological and behavioral deficits in schizophrenia. This review explains the role of serotonergic receptors and oxidative stress, with the aim of providing principles for prospect development of compounds to improve therapeutic effects of antischizophrenic drugs.
Keywords: antipsychotic drugs; movement disorders; parkinsonian-like symptoms; tardive dyskinesia.
Figures






Similar articles
-
Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.J Coll Physicians Surg Pak. 2006 Aug;16(8):556-62. J Coll Physicians Surg Pak. 2006. PMID: 16899192 Review.
-
[Dysphagia or dysphagias during neuroleptic medication?].Encephale. 2012 Sep;38(4):351-5. doi: 10.1016/j.encep.2011.07.002. Epub 2011 Oct 11. Encephale. 2012. PMID: 22980477 French.
-
Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S49-57. doi: 10.1097/00004850-199803003-00009. Int Clin Psychopharmacol. 1998. PMID: 9690971 Review.
-
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Prog Brain Res. 2008. PMID: 18772033 Review.
-
[Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].Encephale. 2016 Jun;42(3):248-54. doi: 10.1016/j.encep.2015.12.021. Epub 2016 Feb 26. Encephale. 2016. PMID: 26922134 Review. French.
Cited by
-
Levofloxacin-Induced Oromandibular Dystonia in a 9-Year-Old Patient.Iran J Child Neurol. 2024 Summer;18(3):151-157. doi: 10.22037/ijcn.v18i3.18054. Epub 2024 Jun 22. Iran J Child Neurol. 2024. PMID: 38988842 Free PMC article.
-
Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.Biomedicines. 2022 Aug 18;10(8):2010. doi: 10.3390/biomedicines10082010. Biomedicines. 2022. PMID: 36009557 Free PMC article. Review.
-
Therapeutic dilemma's: antipsychotics use for neuropsychiatric symptoms of dementia, delirium and insomnia and risk of falling in older adults, a clinical review.Eur Geriatr Med. 2023 Aug;14(4):709-720. doi: 10.1007/s41999-023-00837-3. Epub 2023 Jul 26. Eur Geriatr Med. 2023. PMID: 37495836 Free PMC article. Review.
-
An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders.Antioxidants (Basel). 2022 Feb 10;11(2):353. doi: 10.3390/antiox11020353. Antioxidants (Basel). 2022. PMID: 35204235 Free PMC article. Review.
-
Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare.J Psychopharmacol. 2018 Nov;32(11):1191-1196. doi: 10.1177/0269881118796809. Epub 2018 Sep 20. J Psychopharmacol. 2018. PMID: 30232932 Free PMC article.
References
-
- Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–796. - PubMed
-
- Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources